The mechanisms underlying pathway activation in lung cancer are multifaceted, including mutations in PI3K genes, aberrant expression of PTEN, overexpression of downstream effectors and activation of upstream kinases [20]. This evidence concerns the gene PIK3CA and lung cancer.